



Foundation Medicine is a molecular information company dedicated to providing a complete genomic picture to impact routine cancer care.

As the molecular footprint of cancer is better understood and more targeted cancer therapies are developed against those drivers, there is an ever-growing need to connect the science and medicine of cancer. Foundation Medicine is dedicated to powering this connection and bringing comprehensive genomic analysis to routine cancer care.



A Fully Informative Genomic Tumor Profile

Foundation Medicine is a partner in the advancement of oncology and serves community practices, academic medical centers, and research and development groups to provide actionable molecular information for advancement in the understanding and treatment of cancer.

Foundation Medicine's initial commercial offering is a fully informative genomic tumor profile that uses next-generation sequencing (NGS) to analyze routine clinical specimens (i.e., small amounts of paraffin-embedded tumor). Using this sequence data and proprietary

computational biology, Foundation Medicine detects clinically significant alterations in approximately 200 cancer-related genes. Foundation Medicine then combines this genomic data with the latest scientific and medical data, including therapeutic agents and clinical trials, in an easy-to-use, interpretive report to enable physicians to determine the best possible treatment recommendations for each patient.

Study results presented at ASCO 2011 showed that Foundation Medicine's test demonstrated 100 percent concordance

with conventional, single-gene analyses previously reported by commercial reference laboratories for select cancer-associated mutations. Additionally, 80 percent of the potentially actionable mutations in this study would have been missed by traditional hot spot (single marker) analyses. The study also demonstrated the test's ability to uncover other known, novel or unexpected genomic events such as gene rearrangements, which would be missed by PCR-based methods and that may aid in therapeutic decision-making.

The Challenge: Clinical Grade Results from Clinical Grade Samples

Patient samples used in clinical pathology are often impure and challenging to work with, but for results to be clinically relevant, physicians need high confidence in the sensitivity and specificity of a genomic profile. Foundation Medicine's protocols allow for the identification of cancer-driving alterations that are rare within the clinical sample but potentially important for treatment decisions, consistently achieving greater than 99 percent sensitivity and specificity for alterations present in even a small percent of the sample. Identifying these difficult-to-detect alterations may open the door for important new therapeutic options.

Foundation Medicine's report summarizes the patient's genomic profile in context with available targeted therapies, clinical trials and other relevant data, all prioritized based on clinical utility for the individual patient. Every report is reviewed by a Foundation Medicine oncologist and pathologist with expertise in genomics before it is sent to the physician or laboratory.

TEST RESULTS
Non Small Cell Lung Cancer

Genomic Alterations
 EGFR L858R Mutation
 STK11 Whole Gene Deletion
 TP53 R248L Mutation
 Select Genes With No Alterations Detected
 KRAS wildtype
 ALK - No rearrangement detected

Therapies Associated With Clinical Benefit
 There is one FDA approved therapy specific to the reported genomic alterations in non-small cell lung cancer (see pages 2-3).
 There is some evidence to support a clinical benefit from three FDA approved therapies for tumors with the reported genomic alterations (see pages 2-3).

Clinical Trials
 2 clinical trials may be relevant to tumors with the reported genomic alterations (see pages 7-8).

Solid Foundation, Positioned for Success

Foundation Medicine was founded by world leaders in genome technology, cancer biology and medical oncology from the Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School and Massachusetts Institute of Technology. The company is backed by Third Rock Ventures, Kleiner Perkins Caufield & Byers and Google Ventures — leading venture capitalists in the life sciences, molecular diagnostics and information technology fields.

Since its launch in 2010, Foundation Medicine has secured collaborations with Novartis, Celgene and Johnson & Johnson Pharmaceutical Research & Development, as well as other undisclosed industry partnerships. The company is also engaging in clinical studies with academic medical centers such as Weill Cornell Medical College, MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center and others in the development of its test. Foundation Medicine operates a CLIA-certified laboratory from its headquarters in Cambridge, Massachusetts.

Foundation Medicine's Vision

We envision a transformation in cancer care, where each patient's treatment is informed by a deep understanding of the genomic and other molecular changes that contribute to their disease.

Management Team

Michael Pellini, M.D.

President & Chief Executive Officer

Kevin Krenitsky, M.D.

Chief Operating Officer

Maureen Cronin, Ph.D.

SVP, Research & Product Development

Vincent Miller, M.D.

SVP, Clinical Development

Gary Palmer, M.D., J.D., M.B.A., M.P.H.

SVP, Medical Affairs & Commercial Development

Jeffrey Ross, M.D.

Medical Director, Interim Head of Pathology & Molecular Diagnostics

Board of Directors

Alexis Borisy

Chairman & Co-Founder, Foundation Medicine, & Partner, Third Rock Ventures, LLC

Brook Byers

Investment Partner, Kleiner Perkins Caufield & Byers

Mark Levin

Partner, Third Rock Ventures, LLC

Michael Pellini, M.D.

President & Chief Executive Officer, Foundation Medicine

David Schenkein, M.D.

Chief Executive Officer, Agios Pharmaceuticals, Inc.

Krishna Yeshwant, M.D.

Partner, Google Ventures

Founding Advisors

Levi Garraway, M.D., Ph.D.

Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute

Todd Golub, M.D.

Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School

Eric Lander, Ph.D.

Broad Institute, Harvard Medical School, Massachusetts Institute of Technology

Matthew Meyerson, M.D., Ph.D.

Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute



Investors



Foundation Medicine, Inc.

One Kendall Square, B6501
Cambridge, MA 02139

(617) 418-2200

info@foundationmedicine.com

Media Contact

Dan Budwick

Pure Communications, Inc.

(973) 271-6085